Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03312556 · ClinicalTrials.gov registry record · NA

Treatment of Supine Hypertension in Autonomic Failure (CPAP)

A NA study of Autonomic Failure and Supine Hypertension, sponsored by Vanderbilt University Medical Center.

Recruiting
Registry status
NA
Development phase
12
Enrollment target
1
Study location

NCT03312556: Recruiting NA study of Autonomic Failure and Supine Hypertension, sponsored by Vanderbilt University Medical Center.

NCT03312556 is a NA study of Autonomic Failure and Supine Hypertension that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 12 participants, below the 38-participant average among 11 other Autonomic Failure trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03312556, a NA study of Autonomic Failure and Supine Hypertension, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.

RECRUITING
Registry status
NA
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decreases blood pressure in autonomic failure patients with supine hypertension.

Primary Outcome

change in supine systolic blood pressure from baseline

Interventions

  • DRUG Placebo
  • DEVICE continuous positive airway pressure (CPAP)

Study Locations (1)

Tennessee

  • Autonomic Dysfunction Center/ Vanderbilt University Medical Center - Nashville

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2017-09-21
Est. Completion 2026-12-21
Phase NA

What NCT03312556 shows while recruiting

NCT03312556 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 38-participant average among 11 other Autonomic Failure trials with a reported enrollment target (68% lower).

The record links to 2 conditions, with Autonomic Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT03312556 reports a single indexed study location in Tennessee.

Frequently Asked Questions

What is clinical trial NCT03312556 about?

NCT03312556 is a clinical study titled "Treatment of Supine Hypertension in Autonomic Failure (CPAP)". Supine hypertension is a common problem that affects at least 50% of patients with primary autonomic failure. Supine hypertension can be severe and complicates the treatment of orthostatic hypotension. The purpose of this study is to assess whether continuous positive airway pressure (CPAP) decrease...

What is the current status of trial NCT03312556?

This trial is currently recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2017-09-21. Estimated completion is 2026-12-21.

What conditions does trial NCT03312556 study?

This clinical trial studies the following conditions: Autonomic Failure, Supine Hypertension.

What interventions are being tested in trial NCT03312556?

The interventions under investigation include: Placebo (DRUG), continuous positive airway pressure (CPAP) (DEVICE).

Who is sponsoring clinical trial NCT03312556?

This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03312556 being conducted?

This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autonomic Failure

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03312556's enrollment target sits among peer trials

12 12th of 11 the lowest of 11 other Autonomic Failure trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Autonomic Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02602769 · 12 participants

    Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome

  • NCT02605421 · 12 participants · Phase 2

    Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

  • NCT02619448 · 12 participants · Early Phase 1

    Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

  • NCT03311503 · 12 participants · Phase 1

    Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03312556, the US trial registry maintained by the National Library of Medicine. NCT03312556 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.